TheEdgeResearch
Home / Stocks / EXOZ

eXoZymes, Inc. (EXOZ)

NASDAQ Healthcare Biotechnology
$5.88 ▲ +2.00%
Market Cap
$54.5M
Sector
Healthcare
Industry
Biotechnology
Beta
2.93
52-Wk Range
4.35-18.4
CEO
Michael Heltzen
Country
US
Currency
USD

eXoZymes, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Monrovia, CA, US. The stock last traded at $5.88, up 2.00% on the session, giving a market capitalisation of $54.5M. On trailing twelve-month figures it carries a trailing P/E of -5.11, a net margin of 0.0%. Its beta of 2.93 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-5.11
Price / Sales
0.00
Price / Book
32.52
EV / EBITDA
-5.51
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.76
Current ratio
1.32
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
32
IPO date
2024-11-13
Headquarters
Monrovia, CA, US
About eXoZymes, Inc.

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Comparable companies

eXoZymes, Inc. is most often compared with the following Healthcare names:

ANEBATOSCGTXESLAGLSIONCYSRZNTILTLSATVGN
More research on EXOZ
EXOZ technical analysis EXOZ TheEdge Score Compare against peers
Open full interactive analysis & DCF →